Prof.

BETTUZZI Saverio

Professore di I fascia
Settore scientifico disciplinare:
BIOCHIMICA (BIO/10)
  • Curriculum Vitae
  • Orario di ricevimento
  • Insegnamenti
  • Incarichi
  • Ricerca

Dr. Saverio Bettuzzi received a PhD in Biology in 1981, the University Diploma in Marine Biochemistry in 1983 and the Doctorate in Biochemistry in 1990, all from the University of Bologna, Italy. He was a Postdoctoral Fellow in Biochemistry (1984–1986) at the University of Modena, Italy, and a Research Associate at the Ben May Institute for Cancer Research at the University of Chicago, USA (1987–1989). After returning to Italy, he became a Postdoctoral Fellow in Biochemistry at the University of Modena (1996–2000), Associate Professor of Biochemistry (2001-2005), and Full Professor of Biochemistry (2005-present) at the University of Parma, where he is Vice-Director of COMT. He is Board Member of INBB, Rome, and ESUR (European Section of Urological Research). He leads a research team with several international collaborations, and hosted international meetings. He cloned and identified Clusterin (CLU) as the major over-expressed gene during castration-induced involution of rat prostate in 1989. His research has focused on the understanding of the regulation of expression, and the biological role, of CLU as a tumor suppressor for Prostate, Colon, Ovarian, Lung Cancers and Neuroblastoma. He did original research on the anti-cancer activity of Green Tea Extracts (GTE) and EGCG, and showed that progression of Prostate Cancer can be blocked with GTE in mouse models and humans. He also validated a qPCR method for molecular diagnosis and prognosis of Prostate Cancer in humans. His research team recently discovered and characterized a novel promoter of CLU in humans, called P2. The P2 promoter is epigenetically regulated.

Riceve su appuntamento telefonico o via e-mail

Anno accademico di espletamento: 2019/2020

Anno accademico di espletamento: 2018/2019

Anno accademico di espletamento: 2017/2018

Anno accademico di espletamento: 2016/2017

Anno accademico di espletamento: 2015/2016

Anno accademico di espletamento: 2014/2015

Anno accademico di espletamento: 2013/2014

Docente di riferimento

Other appointments

Consigliere di Amministrazione dell'Università di Parma dal 2017

Vice Presidente e membro del Consiglio Direttivo di COMT, Centro interdipartimentale di Oncologia Molecolare e Translazionale, Università di Parma (http://www.unipr.it/ateneo/organi-e-strutture/centri-e-altre-strutture/c...)

Membro del Direttivo INBB, Istituto Nazionale Biostrutture e Biosistemi, Roma, per il quale ogni anno organizza il congresso nazionale (www.inbb.it)

Membro del Collegio dei Docenti del Dottorato di Medicina Molecolare

visiting professor

Visiting Professor presso Università di Yangon, Myanmar, marzo 2020

Linee di ricerca

Scientific interests (key words): Clusterin (CLU), Prostate Cancer (PCa), Green Tea, Catechins, Polyphenols, EGCG, Chemoprevention, Biology of Cancer, Prostate, Cell Growth, Metabolism, Androgen Action, Polyamines, Gene expression, Epigenetic Regulation of Gene Expression. Research achievements: 1989, cloning and identification of CLU as the major over-expressed gene during castration-induced involution of rat prostate gland; 1991, human CLU maps to chromosome 8; 1992-1995, CLU is involved in ageing and atrophy in rat prostate; 1999, CLU is down-regulated during cell-cycle progression; 2000, CLU gene is repressed during PCa progression by Nothern Blot analyses; 2002, CLU controls the growth of immortalized human prostate epithelial cells; 2003, identification of a gene signature for diagnosis and prognosis of human PCa; 2004, down-regulation and tissue localization of CLU in human PCa; 2005, identification of nuclear CLU as a pro-apoptotic factor inducing anoikis-death in prostate cancer cells; CLU is a tumor-suppressor factor for PCa in the TRAMP mice model, and in human colon cancer (p21-dependent); 2006, phase II clinical trial for chemoprevention of PCa progression in HG-PIN volunteers by administration of Green Tea Catechins extract (GTE); validation of a qPCR method for molecular diagnosis and prognosis of PCa in the TRAMP model; 2007, nCLU disrupt cell cytoskeleton by interaction with α-actinin; 2008, follow-up clinical trial for confirmation of effective and durable treatment of PCa early lesions by administration of GTE to HGPIN patients; 2009, generation of the TRAMP-CLU KO and MYCN-CLU KO transgenic models: CLU is a tumor suppressor in PCa and in Neuroblastoma; 2011, CLU is a marker of prostate damage and inflammation caused by endocrine disruptors (Bisphenol A); 2012, differential regulation of soluble and nuclear CLU in PCa cells by mda-7/IL-24; nCLU expression sensitizes ovarian cancer cells to paclitaxel; GTE cause collapse of Golgi apparatus in PCa cells; 2013, high CLU expression linked to favourable prognosis of lung cancer; 2014, GTE induces endoplasmic reticulum stress and kills immortalized PNT1a cells by anoikis, tumorigenic PC3 by necroptosis; 2015, discovery and functional characterization of the novel human P2 promoter of CLU; 2018, GTE improves cardiomycytes functions and calcium dynamics; 2019, CLU silencing induces matrix metalloproteinases and promote carcinogenesis by an NF-kB-dependent mechanism.

Pubblicazioni

Orcid

0000-0003-2080-6979

Contatti

Telefono
903803
FAX

903802

Ubicazione dell'ufficio

Plesso Biotecnologico, Sezione Biochimica, Via Volturno 39 - 43100 Parma (PR)